Figure 1
Treatment and follow-up. Treatment and design schema (A) and patient follow-up diagram (B). Reduction phase COP: cyclophosphamide, Oncovin (vincristine), and prednisone.4 Induction phase COPADM1 and COPADM2: cyclophosphamide, Oncovin (vincristine), prednisone, Adriamycin (doxorubicin), and methotrexate.4 Intensification phase CYVE or mini CYVE: cytosine arabinosine 3 g/m2 versus 2 g/m2 and etoposide 200 mg/m2 versus 100 mg/m2.4 Maintenance phase: maintenance 1, 2, 3 and 4.4 Rectangles indicate approximate times of treatment failure events; SMN, secondary malignant neoplasm.

Treatment and follow-up. Treatment and design schema (A) and patient follow-up diagram (B). Reduction phase COP: cyclophosphamide, Oncovin (vincristine), and prednisone. Induction phase COPADM1 and COPADM2: cyclophosphamide, Oncovin (vincristine), prednisone, Adriamycin (doxorubicin), and methotrexate. Intensification phase CYVE or mini CYVE: cytosine arabinosine 3 g/m2 versus 2 g/m2 and etoposide 200 mg/m2 versus 100 mg/m2. Maintenance phase: maintenance 1, 2, 3 and 4. Rectangles indicate approximate times of treatment failure events; SMN, secondary malignant neoplasm.

Close Modal

or Create an Account

Close Modal
Close Modal